BIODELIVERY SCIENCES INTERNATIONAL INC
BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI): 5 pipeline candidates · ~16 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
15.5 months
D/E 0.73 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for BIODELIVERY SCIENCES INTERNATIONAL INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$114.3M
Quarterly Burn
$27.2M
Runway
15.5 mo
Revenue
$43.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| belbuca | Approved |
| elyxyb | Approved |
| onsolis | Approved |
| onsolis/breakyl/painkyl | Approved |
| symproic | Approved |
Frequently asked questions
How many drug candidates are in BIODELIVERY SCIENCES INTERNATIONAL INC's pipeline?
BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BIODELIVERY SCIENCES INTERNATIONAL INC's lead drug candidate?
BIODELIVERY SCIENCES INTERNATIONAL INC's most advanced tracked candidate is belbuca (Approved) for Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
What is BIODELIVERY SCIENCES INTERNATIONAL INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BIODELIVERY SCIENCES INTERNATIONAL INC has approximately 15.5 months of cash runway.
Who is the CEO of BIODELIVERY SCIENCES INTERNATIONAL INC?
Jeffrey Bailey is the chief executive officer of BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI).
Get the full picture on BIODELIVERY SCIENCES INTERNATIONAL INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.